1. Home
  2. AEF vs RIGL Comparison

AEF vs RIGL Comparison

Compare AEF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AEF
  • RIGL
  • Stock Information
  • Founded
  • AEF 1989
  • RIGL 1996
  • Country
  • AEF United States
  • RIGL United States
  • Employees
  • AEF N/A
  • RIGL N/A
  • Industry
  • AEF Finance/Investors Services
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • AEF Finance
  • RIGL Health Care
  • Exchange
  • AEF Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • AEF 268.0M
  • RIGL 486.4M
  • IPO Year
  • AEF N/A
  • RIGL 2000
  • Fundamental
  • Price
  • AEF $5.21
  • RIGL $17.32
  • Analyst Decision
  • AEF
  • RIGL Buy
  • Analyst Count
  • AEF 0
  • RIGL 5
  • Target Price
  • AEF N/A
  • RIGL $34.80
  • AVG Volume (30 Days)
  • AEF 92.5K
  • RIGL 316.4K
  • Earning Date
  • AEF 01-01-0001
  • RIGL 11-07-2024
  • Dividend Yield
  • AEF 7.13%
  • RIGL N/A
  • EPS Growth
  • AEF N/A
  • RIGL N/A
  • EPS
  • AEF 0.57
  • RIGL 0.22
  • Revenue
  • AEF N/A
  • RIGL $157,374,000.00
  • Revenue This Year
  • AEF N/A
  • RIGL $48.98
  • Revenue Next Year
  • AEF N/A
  • RIGL $14.43
  • P/E Ratio
  • AEF $8.86
  • RIGL $78.31
  • Revenue Growth
  • AEF N/A
  • RIGL 21.65
  • 52 Week Low
  • AEF $4.40
  • RIGL $7.48
  • 52 Week High
  • AEF $5.53
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • AEF 40.97
  • RIGL 38.25
  • Support Level
  • AEF $5.17
  • RIGL $15.61
  • Resistance Level
  • AEF $5.54
  • RIGL $17.36
  • Average True Range (ATR)
  • AEF 0.06
  • RIGL 1.31
  • MACD
  • AEF -0.02
  • RIGL -0.25
  • Stochastic Oscillator
  • AEF 11.43
  • RIGL 50.75

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. It invests in the public equity and fixed income markets of Chile. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, Private Equity, telecommunication services, healthcare, real estate and industrials.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: